Logo image of IPHA

INNATE PHARMA SA-SPONS ADR (IPHA) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:IPHA - US45781K2042 - ADR

1.95 USD
+0.06 (+3.17%)
Last: 11/28/2025, 7:39:44 PM
Fundamental Rating

2

IPHA gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 534 industry peers in the Biotechnology industry. IPHA may be in some trouble as it scores bad on both profitability and health. IPHA is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

IPHA had negative earnings in the past year.
In the past year IPHA has reported a negative cash flow from operations.
IPHA had negative earnings in each of the past 5 years.
In the past 5 years IPHA always reported negative operating cash flow.
IPHA Yearly Net Income VS EBIT VS OCF VS FCFIPHA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M 200M

1.2 Ratios

IPHA has a Return On Assets (-49.55%) which is in line with its industry peers.
The Return On Equity of IPHA (-895.24%) is worse than 80.15% of its industry peers.
Industry RankSector Rank
ROA -49.55%
ROE -895.24%
ROIC N/A
ROA(3y)-25.61%
ROA(5y)-23.47%
ROE(3y)-227.3%
ROE(5y)-154.41%
ROIC(3y)N/A
ROIC(5y)N/A
IPHA Yearly ROA, ROE, ROICIPHA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300 -400 -500

1.3 Margins

IPHA has a better Gross Margin (49.52%) than 75.47% of its industry peers.
IPHA's Gross Margin has declined in the last couple of years.
IPHA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 49.52%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.49%
GM growth 5Y-4.49%
IPHA Yearly Profit, Operating, Gross MarginsIPHA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300 -400

More info and screens

2

2. Health

2.1 Basic Checks

IPHA does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, IPHA has more shares outstanding
IPHA has more shares outstanding than it did 5 years ago.
The debt/assets ratio for IPHA is higher compared to a year ago.
IPHA Yearly Shares OutstandingIPHA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
IPHA Yearly Total Debt VS Total AssetsIPHA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

IPHA has an Altman-Z score of -6.34. This is a bad value and indicates that IPHA is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -6.34, IPHA is doing worse than 66.10% of the companies in the same industry.
IPHA has a Debt/Equity ratio of 11.55. This is a high value indicating a heavy dependency on external financing.
IPHA has a worse Debt to Equity ratio (11.55) than 82.77% of its industry peers.
Industry RankSector Rank
Debt/Equity 11.55
Debt/FCF N/A
Altman-Z -6.34
ROIC/WACCN/A
WACC6.9%
IPHA Yearly LT Debt VS Equity VS FCFIPHA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M 200M

2.3 Liquidity

A Current Ratio of 2.21 indicates that IPHA has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 2.21, IPHA is doing worse than 72.85% of the companies in the same industry.
A Quick Ratio of 2.21 indicates that IPHA has no problem at all paying its short term obligations.
IPHA's Quick ratio of 2.21 is on the low side compared to the rest of the industry. IPHA is outperformed by 70.60% of its industry peers.
Industry RankSector Rank
Current Ratio 2.21
Quick Ratio 2.21
IPHA Yearly Current Assets VS Current LiabilitesIPHA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

3

3. Growth

3.1 Past

The earnings per share for IPHA have decreased strongly by -30.42% in the last year.
IPHA shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -75.86%.
Measured over the past years, IPHA shows a very negative growth in Revenue. The Revenue has been decreasing by -28.80% on average per year.
EPS 1Y (TTM)-30.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%19.82%
Revenue 1Y (TTM)-75.86%
Revenue growth 3Y1.38%
Revenue growth 5Y-28.8%
Sales Q2Q%-79.85%

3.2 Future

IPHA is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -3.57% yearly.
Based on estimates for the next years, IPHA will show a very strong growth in Revenue. The Revenue will grow by 43.06% on average per year.
EPS Next Y-32.84%
EPS Next 2Y-10.27%
EPS Next 3Y-3.57%
EPS Next 5YN/A
Revenue Next Year-26.21%
Revenue Next 2Y3.03%
Revenue Next 3Y2.3%
Revenue Next 5Y43.06%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
IPHA Yearly Revenue VS EstimatesIPHA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 100M 200M 300M
IPHA Yearly EPS VS EstimatesIPHA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 -0.2 -0.4 -0.6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for IPHA. In the last year negative earnings were reported.
Also next year IPHA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IPHA Price Earnings VS Forward Price EarningsIPHA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IPHA Per share dataIPHA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4

4.3 Compensation for Growth

IPHA's earnings are expected to decrease with -3.57% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-10.27%
EPS Next 3Y-3.57%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for IPHA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

INNATE PHARMA SA-SPONS ADR

NASDAQ:IPHA (11/28/2025, 7:39:44 PM)

1.95

+0.06 (+3.17%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13 2025-11-13/bmo
Earnings (Next)N/A N/A
Inst Owners10.18%
Inst Owner Change-18.25%
Ins Owners0.92%
Ins Owner ChangeN/A
Market Cap179.73M
Revenue(TTM)6.00M
Net Income(TTM)-46.05M
Analysts80
Price Target5.67 (190.77%)
Short Float %0.09%
Short Ratio0.24
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-7.33%
PT rev (3m)-10.85%
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)-230.42%
EPS NY rev (3m)-258.65%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-18.95%
Revenue NY rev (3m)-72.88%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 25.9
P/FCF N/A
P/OCF N/A
P/B 30.21
P/tB 30.21
EV/EBITDA N/A
EPS(TTM)-0.6
EYN/A
EPS(NY)-0.54
Fwd EYN/A
FCF(TTM)-0.52
FCFYN/A
OCF(TTM)-0.52
OCFYN/A
SpS0.08
BVpS0.06
TBVpS0.06
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -49.55%
ROE -895.24%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 49.52%
FCFM N/A
ROA(3y)-25.61%
ROA(5y)-23.47%
ROE(3y)-227.3%
ROE(5y)-154.41%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.49%
GM growth 5Y-4.49%
F-Score1
Asset Turnover0.06
Health
Industry RankSector Rank
Debt/Equity 11.55
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 10.84%
Cap/Sales 2.82%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.21
Quick Ratio 2.21
Altman-Z -6.34
F-Score1
WACC6.9%
ROIC/WACCN/A
Cap/Depr(3y)22.77%
Cap/Depr(5y)23.45%
Cap/Sales(3y)3.3%
Cap/Sales(5y)8.22%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-30.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%19.82%
EPS Next Y-32.84%
EPS Next 2Y-10.27%
EPS Next 3Y-3.57%
EPS Next 5YN/A
Revenue 1Y (TTM)-75.86%
Revenue growth 3Y1.38%
Revenue growth 5Y-28.8%
Sales Q2Q%-79.85%
Revenue Next Year-26.21%
Revenue Next 2Y3.03%
Revenue Next 3Y2.3%
Revenue Next 5Y43.06%
EBIT growth 1Y-31.37%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year283.08%
EBIT Next 3Y30.44%
EBIT Next 5YN/A
FCF growth 1Y-25.63%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-29.1%
OCF growth 3YN/A
OCF growth 5YN/A

INNATE PHARMA SA-SPONS ADR / IPHA FAQ

What is the ChartMill fundamental rating of INNATE PHARMA SA-SPONS ADR (IPHA) stock?

ChartMill assigns a fundamental rating of 2 / 10 to IPHA.


What is the valuation status for IPHA stock?

ChartMill assigns a valuation rating of 0 / 10 to INNATE PHARMA SA-SPONS ADR (IPHA). This can be considered as Overvalued.


What is the profitability of IPHA stock?

INNATE PHARMA SA-SPONS ADR (IPHA) has a profitability rating of 1 / 10.


What is the financial health of INNATE PHARMA SA-SPONS ADR (IPHA) stock?

The financial health rating of INNATE PHARMA SA-SPONS ADR (IPHA) is 2 / 10.